Adolescents who use cannabis could face a significantly higher risk of developing serious psychiatric disorders by young adulthood, according to a large study published in JAMA Health Forum. The ...
The FDA has approved milsaperidone (Bysanti, Vanda Pharmaceuticals) as first-line treatment for acute manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia ...
Managing bipolar I disorder (BD-I) is a long-term commitment, and factors such as symptoms and side effects influence treatment planning. While switching medications may sometimes be necessary, ...
As marijuana use among teens has grown in the past decade, researchers have been trying to better understand the health risks of the drug. Now, a new longitudinal study finds that cannabis use among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results